|
|
 |
|
|
|
|
6. H. G. Grabowski. Blood money? Critics question high pharmaceutical profits. Sci Am: 115, August, 1993. |
|
|
|
|
|
|
|
|
7. H. Grabowski and J. Vernon. A new look at the returns and risks to pharmaceutical R&D. Management Science 36: 804, 1990. |
|
|
|
|
|
|
|
|
8. K. Wilson, K. Bryan, and R. Faulkner. The industry as patient: Bringing it back to health. Pharmaceutical Executive 13: 84, July, 1993. |
|
|
|
|
|
|
|
|
9. P. Flanagan. Drug Prices: What's the Rationale? Management Review: 10, July, 1993. |
|
|
|
|
|
|
|
|
10. PMA Annual Survey Report: Trends in US Pharmaceutical Sales and R&D. Pharmaceutical Manufacturers Association, Washington, DC, 1993. |
|
|
|
|
|
|
|
|
11. W. vonWartburg. In The Management of Pharmaceutical R&D: The Keys to Success. D. Harnden and D. Macarthur, Eds. PJB Publications, Ltd., New York, 1990, p. 114. |
|
|
|
|
|
|
|
|
12. J. Drews. Strategies for successfully managing pharmaceutical research and development in the 1990s. Drug Information Journal 26: 635, 1992. |
|
|
|
|
|
|
|
|
13. D. Harnden and D. Macarthur. In The Management of Pharmaceutical R&D: The Keys to Success. PJB Publications, Ltd., New York, 1990. |
|
|
|
|
|
|
|
|
14. I. Krause and J. Liu. Benchmarking R&D productivity. Planning Review: 16, January-February, 1993. |
|
|
|
|
|
|
|
|
15. J. D. Coombes. In The Management of Pharmaceutical R&D: The Keys to Success. D. Harnden and D. Macarthur, Eds. PJB Publications, Ltd., New York, 1990, p. 120124. |
|
|
|
|
|
|
|
|
16. J. Drews. In the Management of Pharmaceutical R&D: The Keys to Success. D. Harnden and D. Macarthur, Eds. PJB Publications, Ltd., New York, 1990, p. 108. |
|
|
|
|
|
|
|
|
17. J. Drews. The impact of globalization on pharmaceutical research and development. Drug Information Journal 27: 1059, 1993. |
|
|
|
|
|
|
|
|
18. A. B. Chivvis, D. J. Mackie, and N. C. Selby. Playing to win the new game in pharmaceuticals. Pharmaceutical Executive 7: 50, 1987. |
|
|
|
|
|
|
|
|
19. E. Broshy. A race to the finish in the development game. Pharmaceutical Executive 11: 70, 1991. |
|
|
|
|
|
|
|
|
20. E. Rule. Squeeze time for speedier drug approvals. Pharmaceutical Executive 13: 72, 1993. |
|
|
|
|
|
|
|
|
21. L. Soyka. Risks and benefits of global drug development: Resource consideration. Drug Information Journal 27: 1095, 1993. |
|
|
|
|
|
|
|
|
22. E. Philipp and T. R. Weihrauch. Multinational drug development and clinical research: A bird's eye view of principles and practice. Drug Information Journal 27: 1121, 1993. |
|
|
|
|
|
|
|
|
23. R. Sykes. In The Management of Pharmaceutical R&D: The Keys to Success. D. Harnden and D. Macarthur, Eds. PJB Publications, Ltd., New York, 1990, p. 112. |
|
|
|
|
|
|
|
|
24. O. Harari. Working Smart: The New Strategic Imperative. Management Review: 30, May, 1994B. |
|
|
|
|
|
|
|
|
25. M. K. Allio. 3M's sophisticated formula for teamwork. Planning Review: 19, November/December, 1993. |
|
|
|
|
|
|
|
|
26. L. L. Miller. Risk/benefit assessment: The greased pig of drug development. Drug Information Journal 27: 1011, 1993. |
|
|
|
|
|